Top in hem/onc: Survival benefits of cancer drugs, updates in colorectal cancer screening
A recent study showed that most cancer therapies tested in phase 3 trials lack survival benefits, prompting researchers to advocate for more stringent criteria to determine which therapies should advance to phase 3 development.
A report on the data was the top story in hematology/oncology last week.
The second top story was about updated recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which focus on when to start and stop colorectal cancer screening for average-risk individuals.
Read these and more top stories in hematology/oncology below:
Most therapies tested in phase 3 cancer trials fail to confer meaningful survival benefit
More than 80% of therapies tested in phase 3 oncology trials did not demonstrate clinically meaningful benefit in extending survival, according to results of a study published in JNCCN — Journal of the National Comprehensive Cancer Network. Read more.
U.S. Multi-Society Task Force on Colorectal Cancer updates screening recommendations
The U.S. Multi-Society Task Force on Colorectal Cancer updated its screening recommendations. Read more.
Immunotherapy before targeted therapy extends OS in metastatic melanoma
Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings. Read more.
FDA approves Besremi for polycythemia vera
The FDA approved ropeginterferon alfa-2b-njft (Besremi, PharmaEssentia), monopegylated, long-acting interferon, for the treatment of adults with polycythemia vera. Read more.
Fasting-mimicking diet safe, may benefit patients on anticancer therapy
A cyclic, 5-day fasting-mimicking diet appeared safe and showed potential to improve outcomes among patients on anticancer therapy for different tumor types, according to study results published in Cancer Discovery. Read more.